share_log

Carnegie Capital Asset Management LLC Trims Stake in CVS Health Co. (NYSE:CVS)

Carnegie Capital Asset Management LLC Trims Stake in CVS Health Co. (NYSE:CVS)

Carnegie Capital Asset Management LLC Trims持有CVS Health Co.(紐約證券交易所代碼:CVS)的股份
Defense World ·  2022/09/24 11:11

Carnegie Capital Asset Management LLC lowered its position in CVS Health Co. (NYSE:CVS – Get Rating) by 88.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,716 shares of the pharmacy operator's stock after selling 36,167 shares during the quarter. Carnegie Capital Asset Management LLC's holdings in CVS Health were worth $394,000 at the end of the most recent reporting period.

卡內基資本資產管理有限責任公司(Carnegie Capital Asset Management LLC)在最近一次向美國證券交易委員會(Securities And Exchange Commission)披露的信息中稱,該公司第二季度將其在CVS Health Co.(NYSE:CVS-GET Rating)的持倉下調了88.5%。該公司在本季度出售了36,167股後,持有這家藥房運營商的4,716股股票。在最近一個報告期結束時,卡內基資本資產管理有限責任公司在CVS Health持有的股份價值394,000美元。

Other hedge funds and other institutional investors have also made changes to their positions in the company. Macroview Investment Management LLC increased its position in shares of CVS Health by 128.3% during the first quarter. Macroview Investment Management LLC now owns 242 shares of the pharmacy operator's stock worth $25,000 after acquiring an additional 136 shares during the period. Claremont Financial Group Inc. bought a new position in CVS Health in the fourth quarter worth approximately $26,000. Stuart Chaussee & Associates Inc. grew its stake in CVS Health by 123.0% in the first quarter. Stuart Chaussee & Associates Inc. now owns 310 shares of the pharmacy operator's stock worth $31,000 after purchasing an additional 171 shares in the last quarter. Rise Advisors LLC bought a new position in CVS Health in the fourth quarter worth approximately $41,000. Finally, Carl Stuart Investment Advisor Inc. bought a new position in CVS Health in the first quarter worth approximately $41,000. Hedge funds and other institutional investors own 77.64% of the company's stock.

其他對衝基金和其他機構投資者也改變了他們在該公司的頭寸。宏景投資管理有限公司在第一季度將其在CVS Health股票的持倉增加了128.3%。宏景投資管理有限責任公司現在擁有242股這家藥房運營商的股票,價值2.5萬美元,在此期間又購買了136股。克萊蒙特金融集團公司在第四季度購買了CVS Health的一個新頭寸,價值約2.6萬美元。今年第一季度,Stuart Chaussee&Associates Inc.在CVS Health的持股增加了123.0%。Stuart Chaussee&Associates Inc.現在持有這家藥房運營商310股股票,價值3.1萬美元,該公司在上個季度又購買了171股。Rise Advisors LLC在第四季度購買了CVS Health的一個新頭寸,價值約41,000美元。最後,卡爾·斯圖爾特投資顧問公司在第一季度購買了CVS Health的一個新頭寸,價值約41,000美元。對衝基金和其他機構投資者持有該公司77.64%的股票。

Get
到達
CVS Health
CVS運行狀況
alerts:
警報:

CVS Health Stock Performance

CVS Health股票表現

Shares of CVS stock opened at $98.35 on Friday. The firm has a market capitalization of $129.12 billion, a price-to-earnings ratio of 15.99, a price-to-earnings-growth ratio of 1.52 and a beta of 0.73. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.91 and a quick ratio of 0.65. The business has a fifty day moving average of $100.20 and a 200 day moving average of $99.25. CVS Health Co. has a 1 year low of $81.78 and a 1 year high of $111.25.

CVS股票上週五開盤報98.35美元。該公司市值為1,291.2億美元,市盈率為15.99倍,市盈率為1.52倍,貝塔係數為0.73。該公司的債務權益比為0.67,流動比率為0.91,速動比率為0.65。該業務的50日移動均線切入位為100.20美元,200日移動均線切入位為99.25美元。CVS Health Co.的一年低點為81.78美元,一年高位為111.25美元。

CVS Health (NYSE:CVS – Get Rating) last released its quarterly earnings data on Wednesday, August 3rd. The pharmacy operator reported $2.40 earnings per share for the quarter, beating analysts' consensus estimates of $2.16 by $0.24. The business had revenue of $80.64 billion during the quarter, compared to analyst estimates of $76.38 billion. CVS Health had a return on equity of 15.19% and a net margin of 2.65%. The company's revenue was up 11.0% on a year-over-year basis. During the same quarter last year, the business posted $2.42 EPS. As a group, research analysts expect that CVS Health Co. will post 8.53 earnings per share for the current year.
CVS Health(NYSE:CVS-GET Rating)最近一次發佈季度收益數據是在8月3日星期三。這家藥房運營商公佈本季度每股收益為2.40美元,比分析師普遍預期的2.16美元高出0.24美元。該業務本季度營收為806.4億美元,而分析師預期為763.8億美元。CVS Health的股本回報率為15.19%,淨利潤率為2.65%。該公司的收入同比增長了11.0%。去年同一季度,該業務公佈的每股收益為2.42美元。研究分析師預計,作為一個整體,CVS Health Co.本年度每股收益將達到8.53美元。

CVS Health Announces Dividend

CVS Health宣佈分紅

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 21st will be paid a dividend of $0.55 per share. The ex-dividend date of this dividend is Thursday, October 20th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.24%. CVS Health's payout ratio is currently 35.77%.

該公司最近還披露了季度股息,將於11月1日(星期二)支付。10月21日(星期五)登記在冊的股東將獲得每股0.55美元的股息。本次股息除息日期為10月20日(星期四)。這意味着年化股息為2.20美元,股息收益率為2.24%。CVS Health的派息率目前為35.77%。

Insider Buying and Selling at CVS Health

CVS Health的內幕買賣

In other news, EVP Alan Lotvin sold 22,541 shares of the firm's stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $104.00, for a total transaction of $2,344,264.00. Following the sale, the executive vice president now directly owns 109,183 shares in the company, valued at approximately $11,355,032. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Thomas M. Moriarty sold 138,654 shares of the firm's stock in a transaction dated Tuesday, June 28th. The stock was sold at an average price of $95.00, for a total transaction of $13,172,130.00. Following the sale, the executive vice president now directly owns 626,273 shares in the company, valued at approximately $59,495,935. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Alan Lotvin sold 22,541 shares of the firm's stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $104.00, for a total value of $2,344,264.00. Following the sale, the executive vice president now owns 109,183 shares in the company, valued at $11,355,032. The disclosure for this sale can be found here. Company insiders own 0.69% of the company's stock.

在其他新聞方面,執行副總裁艾倫·洛文在一筆日期為8月4日(星期四)的交易中出售了22,541股公司股票。股票以104.00美元的平均價格出售,總成交金額為2344264.00美元。出售後,執行副總裁總裁現在直接持有該公司109,183股,價值約11,355,032美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過此超鏈接。在其他新聞方面,執行副總裁託馬斯·M·莫里亞蒂在6月28日(星期二)的交易中出售了138,654股公司股票。股票以95.00美元的平均價格出售,總成交金額為13172130.00美元。出售後,執行副總裁總裁現在直接持有該公司626,273股,價值約59,495,935美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過此超鏈接。此外,執行副總裁艾倫·洛文在一筆日期為8月4日星期四的交易中出售了22,541股公司股票。這些股票的平均價格為104.00美元,總價值為2,344,264.00美元。出售後,執行副總裁總裁現在擁有該公司109,183股,價值11,355,032美元。關於這次銷售的披露可以找到這裏。公司內部人士持有該公司0.69%的股份。

Wall Street Analysts Forecast Growth

華爾街分析師預測經濟增長

CVS has been the topic of several research analyst reports. Credit Suisse Group increased their price objective on CVS Health from $113.00 to $117.00 and gave the stock an "outperform" rating in a research note on Monday, August 8th. Evercore ISI increased their target price on CVS Health from $120.00 to $125.00 and gave the company an "outperform" rating in a research report on Wednesday, September 7th. Mizuho increased their target price on CVS Health from $115.00 to $120.00 and gave the company a "buy" rating in a research report on Monday, August 15th. UBS Group increased their target price on CVS Health from $118.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, August 4th. Finally, Loop Capital began coverage on CVS Health in a research report on Thursday, June 16th. They set a "buy" rating and a $120.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $117.59.

CVS一直是幾份研究分析師報告的主題。瑞士信貸集團將CVS Health的目標價從113.00美元上調至117.00美元,並在8月8日週一的一份研究報告中給出了該股“跑贏大盤”的評級。9月7日,Evercore ISI在一份研究報告中將CVS Health的目標價從120.00美元上調至125.00美元,並給予該公司“跑贏大盤”的評級。瑞穗將CVS Health的目標價從115.00美元上調至120.00美元,並在15日(週一)的一份研究報告中給予該公司“買入”評級。瑞銀集團在8月4日週四的一份研究報告中將CVS Health的目標價從118.00美元上調至127.00美元,並給予該公司“買入”評級。最後,Loop Capital在6月16日星期四的一份研究報告中開始報道CVS Health。他們為該股設定了“買入”評級和120.00美元的目標價。四位股票研究分析師對該股的評級為持有,19位分析師給予了買入評級,一位分析師給予了該公司強烈的買入評級。根據MarketBeat.com的數據,該股目前的普遍評級為“適度買入”,平均目標價為117.59美元。

CVS Health Company Profile

CVS Health公司簡介

(Get Rating)

(獲取評級)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

CVS Health Corporation在美國提供醫療服務。該公司的醫療福利部門提供傳統的、自願的和以消費者為導向的健康保險產品和相關服務。它為僱主團體、個人、大學生、兼職和小時工、健康計劃、醫療保健提供者、政府單位、政府支持的計劃、勞工團體和外籍人士提供服務。

Read More

閲讀更多內容

  • Get a free copy of the StockNews.com research report on CVS Health (CVS)
  • MarketBeat: Week in Review 9/19 – 9/23
  • Why Does Tesla Stock Remain Resilient?
  • Will Crowdstrike Get A Boost From Increased EPS Guidance?
  • Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
  • Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
  • 免費獲取StockNews.com關於CVS Health(CVS)的研究報告
  • MarketBeat:回顧一週9/19-9/23
  • 為什麼特斯拉的股票保持彈性?
  • CrowdStrike是否會從增加每股收益指引中獲得提振?
  • 小盤股的裁員是樓市的晴雨表嗎?
  • 好市多盈利後價格疲軟是買入的好時機嗎?

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS – Get Rating).

想看看還有哪些對衝基金持有簡歷嗎?訪問HoldingsChannel.com獲取CVS Health Co.(紐約證券交易所代碼:CVS-GET Rating)的最新13F文件和內幕交易信息。

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

接受CVS健康日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對CVS Health和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論